As on Wednesday, 10x Genomics Inc (NASDAQ: TXG) got off with the flyer as it spiked 3.03% to $11.89, before settling in for the price of $11.54 at the close. Taking a more long-term approach, TXG posted a 52-week range of $6.78-$18.21.
The Healthcare sector firm’s twelve-monthly sales growth has been -36.10% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -36.10%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 59.53%. This publicly-traded company’s shares outstanding now amounts to $114.36 million, simultaneously with a float of $110.42 million. The organization now has a market capitalization sitting at $1.48 billion.
10x Genomics Inc (TXG) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Health Information Services industry. 10x Genomics Inc’s current insider ownership accounts for 11.30%, in contrast to 97.60% institutional ownership. According to the most recent insider trade that took place on Aug 22 ’25, this organization’s Chief Executive Officer sold 9,348 shares at the rate of 13.79, making the entire transaction reach 128,881 in total value, affecting insider ownership by 945,892. Preceding that transaction, on Aug 22 ’25, Company’s Chief Financial Officer sold 22,315 for 13.79, making the whole transaction’s value amount to 307,657. This particular insider is now the holder of 309,273 in total.
10x Genomics Inc (TXG) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.04 per share during the current fiscal year.
10x Genomics Inc’s EPS increase for this current 12-month fiscal period is 59.53% and is forecasted to reach -0.96 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 23.13% through the next 5 years, which can be compared against the -36.10% growth it accomplished over the previous five years trading on the market.
10x Genomics Inc (NASDAQ: TXG) Trading Performance Indicators
Let’s observe the current performance indicators for 10x Genomics Inc (TXG). It’s Quick Ratio in the last reported quarter now stands at 5.23. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.30. Similarly, its price to free cash flow for trailing twelve months is now 26.02.
In the same vein, TXG’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.70, a figure that is expected to reach -0.29 in the next quarter, and analysts are predicting that it will be -0.96 at the market close of one year from today.
